Fully Human Monoclonal Antibodies that Broadly Neutralize SARS-COV-2
AssigneeOklahoma Medical Research Foundation
InventorKenneth Smith
Life of this patent
Estimating the term…
Abstract
The present invention includes antibodies and antigen-binding fragments thereof that specifically bind a SARS-CoV-2 antigen and are in certain embodiments capable of neutralizing a SARS-CoV-2 infection. Polynucleotides encoding an antibody or an antigen-binding fragment, vectors and host cells that comprise a polynucleotide and pharmaceutical compositions are also included in this invention. Also described herein are methods of using the presently disclosed antibodies, antigen-binding fragments, polynucleotides, vectors, host cells, and compositions to diagnose, prevent or treat a SARS-CoV-2 infection.
Claims24
-43. (canceled)
An antibody (Ab), or antigen (Ag)-binding fragment thereof, capable of binding to a SARS-CoV-2 spike (S) glycoprotein comprising:
- a heavy chain variable domain (VH) that comprises complementarity determining region (CDR)H1, CDRH2, and CDRH3 amino acid sequences set forth in SEQ ID NO.:
- 1 or 11, SEQ ID NO.:
- 2 or 12 and SEQ ID NO.:
- 3 or 13, respectively, and
- a light chain variable domain (VL) that comprises CDRL1, CDRL2, and CDRL3 amino acid sequences set forth in SEQ ID NO.:
- 6 or 16, SEQ ID NO.:
- 7 or 17, and SEQ ID NO.:
- 8 or 18, respectively.
A method of treating a mammalian or human subject infected with SARS-Cov-2 or preventing SARS-CoV-2 infection in a subject at risk of infection with SARS-CoV-2 comprising administering to a subject in need thereof a therapeutically effective amount of a SARS-CoV-2 neutralizing Ab or Ag-binding fragment.
A method of detecting SARS-CoV-2 infection in a a mammalian or human subject comprising the steps of:
- (a) contacting a sample from the subject suspected to be infected with SARS-CoV-2 with an Ab or Ag-binding fragment capable of binding to a SARS-CoV-2 spike (S) glycoprotein.
- (b) detecting binding of the Ab or Ab fragment to a SARS-CoV-2 Ag in the sample.
A kit for the detection of SARS-Cov-2 infection in a subject comprising:
- (a) an Ab or Ag-binding fragment capable of binding to a SARS-CoV-2 spike (S) glycoprotein, (b) a suitable container, and (c) an immunodetection reagent.
Dependencies are inferred from the claim text.